erlotinib hydrochloride has been researched along with Kidney Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, MJ; Choi, HD | 1 |
| Egido, J; Falke, LL; Goldschmeding, R; Mezzano, S; Morgado-Pascual, JL; Ortiz, A; Rayego-Mateos, S; Rodrigues-Diez, R; Rodrigues-Diez, RR; Ruiz-Ortega, M | 1 |
| Arcidiacono, MV; Dusso, A; Fernandez, E; Yang, J | 1 |
| Edelman, MJ; Hohl, RJ; Hollis, DR; Kindler, HL; Lewis, LD; Lichtman, SM; Marshall, JL; Miller, AA; Murry, DJ; Owzar, K; Ratain, MJ; Villalona-Calero, MA | 1 |
1 review(s) available for erlotinib hydrochloride and Kidney Diseases
| Article | Year |
|---|---|
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Digestive System Diseases; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye; Eye Diseases; Female; Gastrointestinal Tract; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors | 2020 |
1 trial(s) available for erlotinib hydrochloride and Kidney Diseases
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kidney Diseases; Kidney Function Tests; Liver Diseases; Liver Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
2 other study(ies) available for erlotinib hydrochloride and Kidney Diseases
| Article | Year |
|---|---|
Connective tissue growth factor induces renal fibrosis via epidermal growth factor receptor activation.
Topics: Animals; Connective Tissue Growth Factor; Disease Models, Animal; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Fibrosis; Folic Acid; G2 Phase Cell Cycle Checkpoints; Humans; Kidney; Kidney Diseases; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; NIH 3T3 Cells; Peptide Fragments; Protein Kinase Inhibitors; Receptor, trkA; Signal Transduction; STAT3 Transcription Factor | 2018 |
The induction of C/EBPβ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Calcitriol; CCAAT-Enhancer-Binding Protein-beta; Cell Proliferation; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Immunoenzyme Techniques; Kidney Diseases; Parathyroid Glands; Parathyroid Hormone; Rats; Real-Time Polymerase Chain Reaction; Receptors, Calcitriol; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor alpha; Vitamin D; Vitamins | 2015 |